Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neuroblastoma: early-phase trial registry
38 of 98 indexed Neuroblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #141 of 28,707 conditions by registered trial count.
98 US clinical trials · 38 currently recruiting · #141 of 28,707 conditions by registered trial count
Neuroblastoma: 98 US clinical trials tracked, 38 recruiting.
Neuroblastoma is the subject of 98 registered US clinical trials on ClinicalTrials.gov, 38 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 78 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition neuroblastoma
OPEN 38 | RECR 39% | LATE 6 | EARLY 78 | RANK #141 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Metastatic Urothelial Carcinoma (39% recruiting · 31 trials)
Neuroblastoma lists 38 open slots (39% of 98 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neuroblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neuroblastoma recruits in line with its size-band peers.
38 of 98 indexed trials (38.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neuroblastoma research.
Memorial Sloan Kettering Cancer Center accounts for 19 of 98 trials (19.4%). 41 distinct sponsors appear on at least one study for this condition label.
-
Most Neuroblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 95 trials that report a genuine target (sentinel values excluded). 66 of those (69.5%) plan for fewer than 100 participants.
-
Neuroblastoma research is mostly interventional.
89 interventional and 9 observational studies make up this index (90.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
98 total, page 2 of 2
A Study of N9 Chemotherapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT04947501
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Baylor College of Medicine
NCT01953900
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
University of Florida
NCT04837547
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
Mayo Clinic
NCT04040088
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
NCT02298348
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
New Approaches to Neuroblastoma Therapy Consortium
NCT02573896
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
St. Jude Children's Research Hospital
NCT03541720
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
Baylor College of Medicine
NCT01192555
3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Baylor College of Medicine
NCT01822652
Rapid Administration Pilot for Infusing Dinutuximab
Children's Hospital Los Angeles
NCT05421897
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
Memorial Sloan Kettering Cancer Center
NCT02307630
Surgery in Treating Children With Neuroblastoma
Children's Oncology Group
NCT00003119
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Children's Oncology Group
NCT00499616
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center
NCT00782145
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
University of California, San Francisco
NCT00293319
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Giselle Sholler
NCT02395666
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Sue O'Dorisio
NCT02441062
Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers
Memorial Sloan Kettering Cancer Center
NCT00608452
iCAT for Recurrent/Refractory/HR Solid Tumors
Dana-Farber Cancer Institute
NCT01853345
New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma
National Cancer Institute (NCI)
NCT00001335
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT02245997
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT02100930
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
Sue O'Dorisio
NCT01869725
Study of MLN8237 in Combination With Irinotecan and Temozolomide
New Approaches to Neuroblastoma Therapy Consortium
NCT01601535
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00410657
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
St. Jude Children's Research Hospital
NCT00187109
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT01183429
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Children's Oncology Group
NCT00082758
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
NCT00109993
N99-02: Melphalan and Buthionine Sulfoximine
New Approaches to Neuroblastoma Therapy Consortium
NCT00005835
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT00003737
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma
Children's Oncology Group
NCT00002740
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00024258
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Giselle Sholler
NCT01059071
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
Baylor College of Medicine
NCT00206388
Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
Baylor College of Medicine
NCT00085930
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
University of Louisville
NCT01241162
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Timothy Cripe
NCT00931931
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Nant Operations Center
NCT00646230
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Cancer Institute (NCI)
NCT02107963
Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy
Malcolm Brenner
NCT00048386
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT01492673
Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma
Baylor College of Medicine
NCT00062855
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT01183416
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
NCT00003661
Chemotherapy in Treating Children With Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
NCT00002730
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
NCT00064311
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University School of Medicine
NCT00003107
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 30 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Neuroblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neuroblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neuroblastoma page
98 registered trials, 38 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 38 Neuroblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Neuroblastoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuroblastoma condition card totals 98 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.